Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast media presented as a solution for intravascular use. It enhances the visibility of vascular structures and organs during diagnostic imaging procedures, facilitating accurate interpretation in patients undergoing radiographic examinations.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and imaging centres worldwide.

Optiray is an iodinated contrast agent used in radiographic pathways that require enhanced vascular and tissue delineation. - Computed Tomography (CT) of the head, chest, abdomen and pelvis: improves lesion detection and anatomic detail. - Angiography (including cerebral, cardiac and peripheral): provides clear visualization of blood‑vessel lumen. - Urography and intravenous pyelogram (IVP): outlines the urinary collecting system for diagnostic assessment.

Adverse reactions to Optiray may range from mild to severe and should be monitored during and after administration.

Common Side Effects: - Warm sensation or flushing at the injection site - Nausea or mild vomiting - Headache - Transient metallic taste - Mild itching or urticaria - Low‑grade hypotension

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylactoid reaction - Acute kidney injury, especially in patients with pre‑existing renal impairment - Cardiovascular collapse - Pulmonary edema - Seizures - Fatal outcomes in rare cases

Before using Optiray, clinicians should assess patient history and follow recommended safety measures. - Renal function assessment: evaluate serum creatinine and eGFR, especially in at‑risk patients. - Allergy history: confirm no prior severe reaction to iodinated contrast. - Hydration status: ensure adequate pre‑ and post‑procedure hydration to reduce nephrotoxicity risk. - Concomitant nephrotoxic drugs: consider dose adjustment or alternative imaging if possible. - Pregnancy and lactation: use only if essential, after risk‑benefit analysis. - Store at below 25°C: keep in original container, protect from light and moisture.

Optiray may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid): - Metformin: risk of lactic acidosis in renal impairment; discontinue before contrast administration. - High‑dose NSAIDs: may exacerbate contrast‑induced nephropathy. - Angiotensin‑converting enzyme inhibitors or ARBs: increase risk of renal dysfunction when combined with contrast.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance, requiring careful monitoring of hydration. - Beta‑blockers: can mask early signs of anaphylactoid reactions. - Thyroid hormones: iodine load may affect thyroid function tests. - Radiopharmaceuticals: consider timing to avoid overlapping imaging artifacts. - Other contrast agents: avoid sequential administration without adequate clearance.